[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337365-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337365-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","plasma-cell-free-dna-as-a-sensitive-biomarker-for-multi-cancer-detection-and-immunotherapy-outcomes-prediction","Plasma cell-free DNA as a sensitive biomarker for multi-cancer detection and immunotherapy outcomes prediction","","Study evaluates whether cfDNA 4 bp-end motifs enable sensitive multi-cancer detection and prediction of immunotherapy responses. Using whole-genome sequencing of plasma cfDNA, 206 participants were split into training and testing cohorts, with cancer classification learned from motif profiles and immunotherapy response modeled separately via random forest. Performance reached high AUC values across cohorts, including strong results in lung and gastrointestinal cancers, with responder identification supported by motif-based sensitivity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/plasma-cell-free-dna-as-a-sensitive-biomarker-for-multi-cancer-detection-and-immunotherapy-outcomes-prediction/337365/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/plasma-cell-free-dna-as-a-sensitive-biomarker-for-multi-cancer-detection-and-immunotherapy-outcomes-prediction/337365.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study’s main goal regarding cfDNA end motifs?","Question",{"text":63,"@type":64},"To assess the utility of cfDNA end motifs for sensitive detection across multiple cancer types and to support prediction of immunotherapy outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were participants and datasets organized in the study?",{"text":68,"@type":64},"The study included 206 participants, with cancer patients covering 20 cancer types and healthy controls, divided into training and testing cohorts. Separate modeling was used for immunotherapy response prediction.",{"name":70,"@type":61,"acceptedAnswer":71},"What sequencing and modeling approach was used to build the detection model?",{"text":72,"@type":64},"Plasma cfDNA samples were profiled by whole-genome sequencing. Random forest models were trained using cfDNA 4 bp-end-motif profiles and evaluated on the testing cohort.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337365,1790160553,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Journal of Cancer Research and Clinical Oncology (2024) 150:7  \n[https://doi.org/10.1007/s00432-023-05521-4](https://doi.org/10.1007/s00432-023-05521-4)  \nPlasma cell‑free DNA as a sensitive biomarker for multi‑cancer detection and immunotherapy outcomes prediction  \nJuqing Xu1,2 · Haiming Chen3,4 · Weifei Fan2 · Mantang Qiu3,4 · Jifeng Feng1  \nReceived: 17 August 2023 / Accepted: 16 November 2023 / Published online: 9 January 2024 © The Author(s) 2024  \nAbstract  \nBackground Cell-free DNA (cfDNA) has shown promise in detecting various cancers, but the diagnostic performance of cfDNA end motifs for multiple cancer types requires verification. This study aimed to assess the utility of cfDNA end motifs for multi-cancer detection.  \nMethods This study included 206 participants: 106 individuals with cancer, representing 20 cancer types, and 100 healthy individuals. The participants were divided into training and testing cohorts. All plasma cfDNA samples were profiled by whole-genome sequencing. A random forest model was constructed using cfDNA 4 bp-end-motif profiles to predict cancer in the training cohort, and its performance was evaluated in the testing cohort. Additionally, a separate random forest model was developed to predict immunotherapy responses.  \nResults In the training cohort, the model based on 4 bp-end-motif profiles achieved an AUC of 0.962 (95% CI 0.936–0.987) . The AUC in the testing cohort was 0.983 (95% CI 0.960–1.000). The model also maintained excellent predictive ability indifferent tumor sub-cohorts, including lung cancer (AUC 0.918, 95% CI 0.862–0.974), gastrointestinal cancer (AUC 0.966, 95% CI 0.938–0.993), and other cancer cohort (AUC 0.859, 95% CI 0.776–0.942). Moreover, the model utilizing 4 bp-endmotif profiles exhibited sensitivity in identifying responders to immunotherapy (AUC 0.784, 95% CI 0.609–0.960) . Conclusion The model based on 4 bp-end-motif profiles demonstrates superior sensitivity in multi-cancer detection. Detection of 4 bp-end-motif profiles may serve as potential predictive biomarkers for cancer immunotherapy.  \nKeywords Cell-free DNA · Multiple cancer · Whole-genome sequencing · Cancer detection  \nJuqing Xu, Haiming Chen, and Weifei Fan contributed equally to this work.  \n* Jifeng Feng [jifeng_feng@163.com](jifeng_feng@163.com)  \n1 Department of Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, China  \n2 Department of Hematology and Oncology, Department of Geriatric Lung Cancer Laboratory, The Affiliated Geriatric Hospital of Nanjing Medical University, Nanjing, China  \n3 Department of Thoracic Surgery, Peking University People’s Hospital, Beijing, China  \n4 Thoracic Oncology Institute, Peking University People’s Hospital, Beijing, China  \nIntroduction  \nCancer is a leading cause of morbidity and mortality worldwide, and the number of newly diagnosed cancer cases per year is increasing (Sung et al. 2021) . Effective diagnosis and prevention are key points for improving patient prognosis. Although new cancer screening methods are available, including low-dose computed tomography (LDCT) for lung cancer scanning and gastrointestinal endoscopy to detect gastroenteric tumors, the detection of tumors and survival rates remain unsatisfactory (Ajani et al. 2022 ; Benson et al. 2021 ; Blandin Knight et al. 2017) . Their usage has been limited due to factors such as radiation exposure, invasion, high false-positive rates, and high costs. Therefore, there isan urgent need to develop a reliable, non-invasion, accurate, and cost-effective approach for detecting cancers.  \nCell-free DNA (cfDNA) is a DNA fragment released into the bloodstream by cell apoptosis or necrosis (Kustanovichet al. 2019) . In cancer patients, a fraction of cfDNA is  \nreleased by tumor cells, which is termed circulating tumor DNA (ctDNA) (Aggarwal et al. 2021) . Accumulating evidence suggests that circulating DNA fragments","cbCairx9qt0XBPq8","https://ap.wps.com/l/cbCairx9qt0XBPq8","pdf",1436019,"English","# Abstract\n# Introduction\n# Methods\n## Participants and cohorts\n## Whole-genome sequencing and motif modeling\n# Results\n## Multi-cancer detection performance\n## Tumor sub-cohort performance\n## Immunotherapy response prediction\n# Conclusion","[{\"question\":\"What was the study’s main goal regarding cfDNA end motifs?\",\"answer\":\"To assess the utility of cfDNA end motifs for sensitive detection across multiple cancer types and to support prediction of immunotherapy outcomes.\"},{\"question\":\"How were participants and datasets organized in the study?\",\"answer\":\"The study included 206 participants, with cancer patients covering 20 cancer types and healthy controls, divided into training and testing cohorts. Separate modeling was used for immunotherapy response prediction.\"},{\"question\":\"What sequencing and modeling approach was used to build the detection model?\",\"answer\":\"Plasma cfDNA samples were profiled by whole-genome sequencing. Random forest models were trained using cfDNA 4 bp-end-motif profiles and evaluated on the testing cohort.\"}]","Plasma cell-free DNA as a sensitive biomarker for multi-cancer detection and immunotherapy outcomes prediction | PDF",1790018816,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c26c26e18a10634f2ace8804a0b0c8a.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9df751461f459558792b48958402f45e.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/072bb8a8d830a7f5dc7a20c4a3adfecc.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a22f3175bb83867fa725374fd1ad7525.webp",980,1301]